<DOC>
	<DOCNO>NCT02386566</DOCNO>
	<brief_summary>The primary objective study determine association prospectively measure disability ( Expanded Disability Status Scale [ EDSS ] ) quality life ( Multiple Sclerosis International Quality Life Questionnaire [ MusiQoL ] ) 3-month interval 1 year real life set multiple sclerosis ( MS ) patient treat natalizumab . The secondary objective study follow : To evaluate cumulative probability sustain EDSS change 1 year follow natalizumab treatment initiation ; To evaluate association disability ( EDSS ) , fatigue ( Fatigue Scale Motor Cognitive Function [ FSMC ] ) , sexual dysfunction ( Multiple Sclerosis Intimacy Sexuality Questionnaire-19 [ MSISQ-19 ] ) , depression ( Beck Depression Inventory-Fast Screen [ BDI-FS ] ) neurocognitive function ( Symbol Digit Modalities Test [ SDMT ] ) EuroQol-5D Questionnaire ( EQ-5D ) 3 6-months interval 1 year initiation natalizumab treatment ; To assess relationship clinical disease-free status ( EDSS increase 1.0 relapse ) MusiQoL 1 year follow natalizumab treatment initiation ; To record number clinical relapse relapse require steroid treatment 3-months interval 1 year initiation natalizumab treatment ; To describe change work impairment ( Work Productivity Activity Impairment MS [ WPAI-MS ] ) 3-months interval 1 year initiation natalizumab treatment ; To describe change percentage disability pension occupation 1 year natalizumab treatment ; To record incidence number Serious Adverse Events ( SAE ) Suspected Unexpected Serious Adverse Reactions ( SUSAR ) throughout study</brief_summary>
	<brief_title>Observational Study Assess Correlation EDSS With Quality Life MS Participants Treated With Natalizumab</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Subjects confirm diagnosis RRMS , per 2010 revise McDonald criterion Subjects satisfy therapeutic indication natalizumab , describe local product label confirm Investigator . ( Patients previous treatment natalizumab also consider eligible last natalizumab infusion least 1 year screen visit study ) Decision treatment natalizumab make screen Patients EDSS score 2.05.5 ( limit inclusive ) Key Patients diagnose coexist brain pathology MS , judgement investigator impact value EDSS QoL . Pure spinal manifestation demyelination Diagnosis primary secondary progressive MS Any change concomitant medication know affect cognition bladder function A history severe depressive disorder and/or suicidality , seizure , drug alcohol abuse , assess Investigator NOTE : Other Protocol Defined Inclusion/ Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>